Therapeutic Asset Ratings

229 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FLUDEOXYGLUCOSE Lymphoma	Rigshospitalet, Denmark	P2	CCC (48)
HUMAN FAECAL MATTER Lymphoma	University Health Network, Toronto	P2	CCC (48)
IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME (HUMAN) CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBOD Lymphoma	Imperial College Healthcare NHS Trust	P2	CCC (48)
immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent Lymphoma	Mabwell (Shanghai) Bioscience Co., Ltd.	P2	CCC (48)
Keppra Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CCC (48)
Mecapegfilgrastim Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (48)
Mit-001 Lymphoma	MitoImmune Therapeutics	P2	CCC (48)
MOGAMULIZUMAB Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Nemtabrutinib Lymphoma	City of Hope Medical Center	P2	CCC (48)
Odronextamab Lymphoma	Gottfried von Keudell, MD PhD	P2	CCC (48)
OGALVIBART Lymphoma	Imperial College Healthcare NHS Trust	P2	CCC (48)
Ptcy Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CCC (48)
Pyruvate Lymphoma	Rigshospitalet, Denmark	P2	CCC (48)
Ruxolitinib Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CCC (48)
sb-497115-gr Lymphoma	National Taiwan University Hospital	P2	CCC (48)
Sonrotoclax Lymphoma	Christine Ryan	P2	CCC (48)
Sotagliflozin Lymphoma	Icahn School of Medicine at Mount Sinai	P2	CCC (48)
Tafasitamab Lymphoma	Brown University	P2	CCC (48)
vi-0609 Lymphoma	VIVUS LLC	P2	CCC (48)
Devimistat Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CC (47)
Fosphenytoin Lymphoma	Center for International Blood and Marrow Transplant Research	P2	CC (47)
Loncastuximab Tesirine Lymphoma	Istituto Clinico Humanitas	P2	CC (47)
Anti-Cd30-Car-Transduced T Cells Lymphoma	Affiliated Hospital of Nantong University	P1/2	CC (46)
ARG Lymphoma	ITM Solucin GmbH	P1/2	CC (46)
cd70-targeting car-t cells Lymphoma	St. Jude Children's Research Hospital	P1/2	CC (46)

Showing 126 to 150 of 229 assets

PreviousPage 6 of 10Next